Citation

Reich M, Kotecki N. Bull. Cancer 2017; 104(5): 442-451.

Copyright

(Copyright © 2017, John Libbey Eurotext)

DOI

10.1016/j.bulcan.2017.01.013

PMID

28318493

Abstract

Bipolar disorders belong to the spectrum of mood disorders and represent a serious psychiatric comorbidity. Behaviors adopted by bipolar patients can foster cancer occurrence but also impact its management, especially during acute depressive or manic episode. Oncologists must adapt their protocols in order to obtain the best compliance for treatment and avoid any possible mood destabilization, with the inherent risk of suicidal attempt. Potential interactions between mood-stabilizing agents (lithium, divalproate, atypical antipsychotics, and anticonvulsivants) and oncologic treatment (chemotherapy, targeted therapy, immunotherapy, corticotherapy) will be particularly watched. To do so, a closely collaboration with the oncopsychiatrist but also with the referent or liaison psychiatry team is necessary during the patient's oncologic care. Some clinical vignettes will illustrate the modalities of care of bipolar disorders in oncology.

Language: fr

Keywords

Humans; Suicide; Neoplasms; Patient Care Team; Bipolar disorders; Cancer; Mood disorders; Patient Compliance; Bipolar Disorder; Mood stabilizer; Antipsychotic Agents; Immunotherapy; Adrenal Cortex Hormones; Antineoplastic Agents; Radiotherapy; Troubles bipolaires; Antipsychotiques atypiques; Atypical antipsychotic drugs; État maniaque; Manic episode; Molecular Targeted Therapy; Thymorégulateur; Troubles de l’humeur